Profound Medical (PRN.TO) Stock Price
Profound Medical Price
Revenue has compounded at 16.3% per year over the past 8 years to 16.38 M USD. Profound Medical's net margin stands at -264.4%, up from -446.7% several years earlier. Analysts set a median price target of 10.91 USD, implying 90.2% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
Profound Medical stock price
Profound Medical business model & stock analysis
Frequently asked questions about Profound Medical
Profound Medical Corp is a medical technology company specializing in the development of real-time magnetic resonance imaging (MRI) guided ablation devices for the treatment of diseases such as prostate cancer. The company's business model revolves around the creation and commercialization of innovative solutions that enable precise and personalized ablation procedures. Profound's devices utilize thermal energy to heat and destroy targeted tissue while providing real-time feedback to clinicians for enhanced safety and efficacy. By leveraging cutting-edge MRI technology, Profound Medical Corp aims to optimize patient outcomes in the field of minimally invasive therapies, positioning itself as a leader in the evolving landscape of image-guided treatments.
Profound Medical Corp is primarily active in the medical industry.
The main competitors of Profound Medical Corp in the market include SonaCare Medical, Inc., EDAP TMS S.A., and Exact Imaging Inc.
Profound Medical Corp is a prominent medical technology company that focuses on developing and commercializing innovative treatments for prostate cancer. Established in 2008, Profound Medical has made significant strides in the field of image-guided therapy. Their flagship product, TULSA-PRO, utilizes MRI and ultrasound technology to deliver precise and personalized thermal ablation treatments, effectively destroying targeted prostate tissue while minimizing damage to surrounding areas. This revolutionary approach provides patients with a non-invasive or minimally invasive option, reducing side effects and improving outcomes. Profound Medical Corp continues to advance the field of prostate cancer treatment, offering hope to patients worldwide.
Profound Medical Corp, a leading medical device company, has achieved several significant milestones. Firstly, they received FDA approval for their revolutionary TULSA-PRO system, which offers non-invasive treatment for prostate cancer. This milestone has positioned Profound Medical Corp as a game-changer in the field of prostate cancer treatments. Additionally, the company successfully completed a clinical trial, showcasing the TULSA-PRO system's remarkable efficacy and safety profile. Furthermore, Profound Medical Corp expanded its market reach by establishing strategic partnerships with renowned cancer centers and leading healthcare providers. Through continuous innovation and collaboration, Profound Medical Corp has cemented its position as a trailblazer in the fight against prostate cancer.
Profound Medical Corp primarily operates in the United States, Canada, and Europe.
Profound Medical Corp is committed to transforming the lives of patients with minimally invasive, incision-free therapies for the treatment of prostate disease. Their corporate philosophy revolves around innovation, patient-centricity, and a dedication to advancing medical technologies. By leveraging their cutting-edge TULSA-PRO® system, Profound Medical Corp aims to provide precise and personalized treatments, reducing potential side effects while enhancing treatment outcomes. With a focus on research and development, they strive to continuously improve their therapeutic offerings and expand their reach globally. Profound Medical Corp's values encompass integrity, collaboration, and a commitment to revolutionizing healthcare through their transformative solutions.
Analysts currently set an average price target of 10.91 USD for the Profound Medical stock (median: 10.91 USD), implying +90.2 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the Profound Medical stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Profound Medical to generate revenue of 25.25 M USD and earnings per share of -0.67 USD.
Converted at the current exchange rate, the Profound Medical share trades at 5.12 EUR (5.74 USD).
The Profound Medical share (PRN.TO) is listed on 2 stock exchanges, including: NASDAQ (PROF), Toronto (PRN.TO).
Profound Medical Corp is a leading company in the development of innovative medical technologies for the treatment of prostate cancer. The company's business model is based on the development and marketing of its advanced therapy systems for the treatment of localized prostate cancer. The divisions of Profound Medical Corp include research and development, marketing and distribution of medical devices. The company focuses on developing medical products that meet the patients' need for state-of-the-art, minimally invasive treatments. The devices of Profound Medical Corp are targeted towards the target group of urologists and radiation therapists. The main product of Profound Medical Corp is the TULSA-PRO® System, an innovative HIFU (High-Intensity Focused Ultrasound) system that enables the minimally invasive treatment of localized prostate cancer. The technology is based on an ultrasound device that destroys the diseased tissue in the prostate using sound waves without damaging the surrounding tissue. The minimally invasive procedure is performed on an outpatient basis and minimizes the risk of complications and side effects. The TULSA-PRO® System offers many advantages compared to other conventional treatment methods. For example, it is gentler and faster than radiation therapy or surgery and has a better success rate than the use of chemotherapy or hormonal therapies. In addition, the TULSA-PRO® System is approved by the FDA, the American Food and Drug Administration, and CE-marked. The company also provides comprehensive training and technical support for users of the TULSA-PRO® System. Therefore, consulting, device management, and continuous maintenance are further services offered by Profound Medical Corp. In the course of its business activities, the company strives for close cooperation with leading research institutions and specialists in the field of cancer treatment. The goal is to develop innovative technologies that improve the diagnosis and treatment of prostate cancer and increase the quality of life of affected patients. In conclusion, the business model of Profound Medical Corp is focused on the needs of patients and their doctors. With the development and marketing of innovative medical devices, the company offers advanced technology that enables minimally invasive treatment of prostate cancer. Through collaboration with leading research institutions, Profound Medical Corp further expands its expertise in the field of cancer treatment.
The expected revenue of Profound Medical is 25.25 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Profound Medical is -20.72 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Profound Medical is currently -8.51. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Profound Medical stock.
The price-to-sales ratio (P/S) of Profound Medical is currently 6.98. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Profound Medical stock.
The Eulerpool Quality Score for Profound Medical is 3/10.
The ISIN of Profound Medical is CA74319B5027. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Profound Medical is PRN.TO. The ticker symbol is used to trade Profound Medical shares on the stock exchange.
Profound Medical stock
Profound Medical Peer Group
Profound Medical Ticker
Profound Medical FIGI
All fundamentals and in-depth analysis of Profound Medical
Our stock analysis for Profound Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Profound Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.